Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $12.00 | Overweight → Equal Weight | Wells Fargo |
| 5/28/2025 | $12.00 | Outperform → Neutral | Wedbush |
| 5/14/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 5/14/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/13/2025 | Overweight → Neutral | Analyst | |
| 8/13/2024 | $31.00 | Overweight | Wells Fargo |
| 12/13/2021 | $37.00 → $54.00 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $55.00 → $54.00 | Outperform | SVB Leerink |
Wells Fargo downgraded iTeos Therapeutics from Overweight to Equal Weight and set a new price target of $12.00
Wedbush downgraded iTeos Therapeutics from Outperform to Neutral and set a new price target of $12.00
Leerink Partners downgraded iTeos Therapeutics from Outperform to Market Perform and set a new price target of $9.00
8-K - iTeos Therapeutics, Inc. (0001808865) (Filer)
SCHEDULE 13D - iTeos Therapeutics, Inc. (0001808865) (Subject)
144 - iTeos Therapeutics, Inc. (0001808865) (Subject)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)
4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)